Multiple primary cancer in Leser — Trelat syndrome (description of a clinical case)

2020 ◽  
Vol 0 (5) ◽  
pp. 65-70
Author(s):  
V. G. Bondar ◽  
O. V. Kayryak ◽  
V. V. Vasiliev ◽  
N. B. Gubergrits ◽  
T. L. Mozhyna
Keyword(s):  
Clinical Case ◽  
Multiple Primary Cancer ◽  
Primary Cancer ◽  
Multiple Primary

Lung and skin multiple primary cancer: clinical case description

Therapy ◽  
2021 ◽  
Vol 3_2021 ◽  
pp. 100-105
Author(s):  
Semenkin A.A. Semenkin ◽  
Vorotilina L.V. Vorotilina ◽  
Sapronenko V.S. Sapronenko ◽  
Zhivilova L.A. Zhivilova ◽  
Drokina O.V. Drokina ◽  
...  
Keyword(s):  
Clinical Case ◽  
Multiple Primary Cancer ◽  
Primary Cancer ◽  
Case Description ◽  
Multiple Primary

scholarly journals Clinical Characteristics of Multiple Primary Cancer in Breast Cancer Patients

2007 ◽  
Vol 10 (4) ◽  
pp. 263 ◽  
Author(s):  
Sang Hee Jung ◽  
Seung Soo Kwak ◽  
Seong Chul Kim ◽  
Moon Ki Park ◽  
Gun Seok Lee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Characteristics ◽  
Multiple Primary Cancer ◽  
Primary Cancer ◽  
Breast Cancer Patients ◽  
Multiple Primary

scholarly journals A Case of Multiple Primary Cancer on Bilateral Maxillary Gingiva

1985 ◽  
Vol 39 (3) ◽  
pp. 385-391
Author(s):  
Hideo Kurokawa ◽  
Minoru Kajiyama ◽  
Nobuto Nomura ◽  
Takahiro Kodama ◽  
Isao Akama ◽  
...  
Keyword(s):  
Multiple Primary Cancer ◽  
Primary Cancer ◽  
Multiple Primary

Clinical Characteristics and Abnormal p53 Expression of Lung Cancer Associated with Multiple Primary Cancer

1999 ◽  
Vol 47 (3) ◽  
pp. 331
Author(s):  
Chang Jin Shin ◽  
Hye Jung Park ◽  
Kyeong Cheol Shin ◽  
Young Ran Shim ◽  
Jin Hong Chung ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Characteristics ◽  
Multiple Primary Cancer ◽  
Primary Cancer ◽  
P53 Expression ◽  
Multiple Primary

scholarly journals A clinical and genetic analysis of multiple primary cancer referrals to genetics services

2014 ◽  
Vol 23 (5) ◽  
pp. 581-587 ◽  
Author(s):  
James Whitworth ◽  
Jon Hoffman ◽  
Cyril Chapman ◽  
Kai Ren Ong ◽  
Fiona Lalloo ◽  
...  
Keyword(s):  
Genetic Analysis ◽  
Multiple Primary Cancer ◽  
Primary Cancer ◽  
Genetics Services ◽  
Multiple Primary

Cancer genes, multiple primary cancer, and von Hippel-Lindau disease

1985 ◽  
Vol 16 (1) ◽  
pp. 13-19 ◽  
Author(s):  
Henry T. Lynch ◽  
David Allan Katz ◽  
Patrick Bogard ◽  
Jane F. Lynch
Keyword(s):  
Multiple Primary Cancer ◽  
Primary Cancer ◽  
Cancer Genes ◽  
Von Hippel Lindau ◽  
Multiple Primary ◽  
Von Hippel Lindau Disease

scholarly journals Risk of multiple primary cancer diagnosis over age in families of Li-Fraumeni syndrome: a single institution perspective

2019 ◽  
Author(s):  
Seung Jun Shin ◽  
Elissa B. Dodd ◽  
Fan Gao ◽  
Jasmina Bojadzieva ◽  
Jingxiao Chen ◽  
...  
Keyword(s):  
Cancer Diagnosis ◽  
Data Availability ◽  
Second Primary ◽  
Multiple Primary Cancer ◽  
Primary Cancer ◽  
Second Primary Cancer ◽  
Li Fraumeni Syndrome ◽  
Mutation Carriers ◽  
Multiple Primary ◽  
Li Fraumeni

AbstractLi-Fraumeni syndrome (LFS) is a rare autosomal dominant disorder associated with TP53 germline mutations and an increased lifetime risk of multiple primary cancers (MPC). Penetrance estimation of time to first and second primary cancer within LFS remains challenging due to limited data availability and the difficulty of accounting for the characteristic effects of a primary cancer on the penetrance of a second primary cancer. Using a recurrent events survival modeling approach, we estimated penetrance for both first and second primary cancer diagnosis from a pediatric sarcoma cohort (number families=189; Single primary cancer, or SPC=771; MPC=87). We then validated the risk prediction performance using an independent clinical cohort of TP53 tested individuals from MD Anderson (SPC=102; MPC=58). Our penetrance estimates are dependent on TP53 genotype, sex, and, importantly, age of diagnosis (AoD) for the first PC. We observed the later the AoD is, the shorter the gap time is for this person to be diagnosed with a second PC. We achieved an Area under the ROC curve (AUC) of 0.77 for predicting individual outcomes of MPC vs. SPC. In summary, we have provided the first set of penetrance estimates for SPC and MPC for TP53 mutation carriers, and demonstrated its accuracy for cancer risk assessment. Our open-source R package, LFSPRO, provides future risk estimates for SPC and MPC among TP53 germline mutation carriers.SignificanceOur tool can be used to support clinical counseling of LFS cancer survivors for better health management.

scholarly journals Study on Multiple Primary Cancer Associated with Esophageal Cancer

2001 ◽  
Vol 26 (4) ◽  
pp. 1109-1113 ◽  
Author(s):  
Koji EMOTO ◽  
Yukishige YAMADA ◽  
Akihiko WATANABE ◽  
Tomoyoshi TAKAYAMA ◽  
Yoshiyuki NAKAJIMA
Keyword(s):  
Esophageal Cancer ◽  
Multiple Primary Cancer ◽  
Primary Cancer ◽  
Multiple Primary

scholarly journals Multiple Primary Cancer and Survival after Lumpectomy with or without Radiotherapy for Ductal Carcinoma in Situ: A Propensity- Score-Matching Study

2021 ◽  
Author(s):  
Yitong Li ◽  
Dengjie Ouyang ◽  
Qitong Chen ◽  
Tao Hong ◽  
Wenjun Yi
Keyword(s):  
Propensity Score ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Second Primary ◽  
Multiple Primary Cancer ◽  
Primary Cancer ◽  
Receptor Status ◽  
Multiple Primary

Abstract Background: Radiotherapy combined with breast-conserving surgery is widely performed in patients with ductal carcinoma in situ (DCIS). This research was conducted to evaluate the use of radiotherapy to reduce the risk of multiple primary cancer (MPC) and mortality in DCIS patients.Methods: 108,416 patients first diagnosed with DCIS between 1998 and 2015 who received lumpectomy in the Surveillance, Epidemiology, and End Results (SEER) 18 database were included. Age, race, year of diagnosis, laterality, pathologic grade, surgery, radiation, estrogen receptor status, progesterone receptor status, tumor size and vital status were extracted. A comparison of lumpectomy vs. lumpectomy plus radiotherapy was performed using 1:1 propensity score-based matching.Results: Of the 108,416 patients, 39,039 patients were treated with lumpectomy alone, and 69,377 were treated with lumpectomy and radiotherapy. The adjusted hazard ratio (HR) for death was 0.801 and 0.7444 for occurrence of MPC in the lumpectomy and radiotherapy vs. lumpectomy alone groups, respectively. Conclusion: Lumpectomy plus radiotherapy is associated with a significant reduction in mortality and risk of MPC, mainly second primary BC. Younger patients, Black women with high-grade tumors were likely to benefit most. Radiotherapy reduced the risk of occurrence rather than the mortality of MPC patients to reduce the overall mortality.

Sign in / Sign up

Export Citation Format

Share Document